Growth Hormone Treatment in Children with Chronic Kidney Disease

Chung, Woo-Yeong

doi:2009.13.1.14

J Korean Soc Pediatr Nephrol > Volume 13(1); 2009 > Article

J Korean Soc Pediatr Nephrol 2009;13(1): 14-20. doi: https://doi.org/10.3339/jkspn.2009.13.1.14

만성 소아 신질환 환자에서의 성장호르몬 치료 인제의대 부산백병원 소아청소년과

정우영

인제대학교 부산백병원 소아청소년과

Growth Hormone Treatment in Children with Chronic Kidney Disease

Woo-Yeong Chung

Department of Pediatrics, College of Medicine, Inje University, Busan Paik Hospital

ABSTRACT

Growth retardation is a common consequenc of chronic kidney disease (CKD) in childhood. Many recent clinical and experimental data indicate that growth failure in CKD is mainly due to a relative GH insensitivity and functional IGF-I deficiency. Glucocorticoids also glucocorticoids interfere with the integrity of the somatotropic hormone axis at various levels. Over the past 10 years, recombinant growth hormone (rhGH) has been used to help short children with chronic kidney disease. A GH dosage of 0.35 mg/kg/week (28 IU/$m^2$/week) appears efficient and safe. Some clinical trial data show that final height will be within the normal target height range when GH treatment is continued for many years without remarkable adverse events.

Key words: Chronic kidney disease | Children | GH/IGF-I axis | GH insensitivity